Addictive properties of drug abuse may hold key to an HIV cure

September 21, 2012

A Florida State University researcher is on a mission to explore the gene-controlling effects of addictive drugs in pursuit of new HIV treatments.

Working under the support of a $1.8 million grant from the National Institutes of Health (NIH), Florida State biologist Jonathan Dennis is studying a unique ability shared between a promising class of known as histone deacetylase inhibitors (HDIs) and such as cocaine.

"Current HIV treatments do just that—they treat the disease by preventing the spread of HIV in the body, rather than eliminating the disease entirely," Dennis said. "I want to find out how to root out those dormant HIV cells that are evading the treatment, and I believe the gene-controlling functions shared by HDIs and psychostimulant drugs hold the key to helping us do that."

HDI and such as cocaine share the ability to control through changes in the chromatin structure within DNA. In the case of HDI treatment, the chromatin changes are used to wake up dormant cells that are hiding in the body.

Dennis believes that addictive drugs do the same thing. Dennis' work will focus on identifying and understanding the overlapping gene changes that occur between these two types of substances, ultimately providing other researchers with the foundational information they need to turn HDI treatments into HIV cures.

To learn more about the scope and purpose of Dennis' NIH grant, visit the grant website. To learn more about Dennis, visit his Department of Biological Science website.

Explore further: New book on HIV from Cold Spring Harbor Laboratory Press

Related Stories

New book on HIV from Cold Spring Harbor Laboratory Press

December 15, 2011
The worldwide AIDS epidemic makes research on HIV, the disease processes it induces, and potential HIV therapies among the most critical in biomedical science. Furthermore, the basic biology of HIV infections provides a model ...

Mechanism of HIV spread has potential for future drug therapy

April 23, 2012
A new understanding of the initial interactions of human immunodeficiency virus type 1 (HIV-1) and dendritic cells is described by Boston University School of Medicine (BUSM) researchers in a study currently featured in the ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.